CD4 and hepatocellular carcinoma: This study lays the groundwork for the further use of MHC II-restricted TCRs in T cell therapy of chronic HBV infection and HBV-induced HCC and provides a valuable tool for the study of CD4+ T cells and their role in HBV infection and cure.